metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-89 ASSESSMENT OF HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS: A CROSS SECTION...
Journal Information
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Share
Share
Download PDF
More article options
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Open Access
P-89 ASSESSMENT OF HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS: A CROSS SECTIONAL ANALYSIS
Visits
368
Mincis Rodrigo1, Altikes Renato Gama1, Vanni Denise Siqueira1, Rossi Da Maria Elizabeth2, Zitteli Patrícia Momoyo1, Carrilho Flair José1, P. Oliveira Claudia1, Pessoa Mario Guimarães1
1 Division of Gastroenterology and Hepatology, Hospital das Clinicas, University of São Paulo School of Medicine
2 Department of Endocrinology, Hospital das Clinicas, University of São Paulo School of Medicine
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 24. Issue S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

More info
Introduction

Metabolic dysfunction associated fatty liver disease (MAFLD) was suggested recently as a more appropriate nomenclature to describe the liver disease associated with known metabolic dysfunction .Type 2 Diabetes is a risk factor for MAFLD, steatohepatitis and patients are at increased risk to developing liver fibrosis and need to be more investigated.

Aim

To investigate which MAFLD patients with type 2 diabetes have higher risk for advanced fibrosis.

Methods

Patients in diabetes clinic, without known hepatic diseases and without significant alcohol intake (< 21 drinks per week), were voluntarily selected to perform liver ultrasound, liver stiffness and CAP measurements using Fibroscan (Echosens, Paris, France) and serological tests for B and C hepatitis to exclude viral causes of liver disease. Subjects were submitted to a complete clinical examination and laboratory tests.

Results

90 patients were included in this cross-sectional analysis. Overall, 12,2% (11 patients) had advanced fibrosis (liver stiffness > 8,7 Kpa) and 23% (21 patients) had severe steatosis (Grade 3 steatosis; CAP> 290 db/m) based on transient elastography. Factors associated with significant fibrosis were age over 60 years old, alanine amino transferase (ALT) elevation, low HDL (lower than 40), triglycerides elevation, higher BMI and severe steatosis.

Conclusion

Prevalence of advanced fibrosis and severe steatosis in patients with type 2 diabetes and MAFLD is very high (12,2% and 23% respectively), what makes screening of these high-risk patients very important. Risk factors such as elevated glycated hemoglobin, higher BMI, triglycerides, ALT and CAP measurements on Fibroscan and low HDL indices are considered to be associated to advanced liver fibrosis.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos